Japan’s largest pharmaceutical company, Takeda, recently signed an agreement with Teva Pharmaceutical Industries to commercialize the Israeli company’s innovative treatment for Parkinson’s disease, rasagiline, in Japan.
The rasagiline tablets, which are approved in over 40 countries for the treatment of Parkinson’s disease, gained UK and EU-marketing authorization in 2005 and US FDA approval in 2006.
“It is estimated there are about 150,000-180,000 people diagnosed with Parkinson’s disease in Japan, many of whom are waiting for a new treatment option,” said Nancy Joseph-Ridge, M.D., General Manager of Takeda’s Pharmaceutical Development Division located in Osaka, Japan in a press release on April 27.
“We will continue working on the development in cooperation with Teva so that we can bring this medicine to Japanese patients as quickly as possible,” Joseph-Ridge said.
“This agreement represents Teva’s continued commitment to introducing our innovative medicines to patients in Japan,” added Teva Global R&D president and Chief Scientific Officer, Dr. Michael Hayden.
Teva and Takeda entered an agreement in December 2013 to develop glatiramer acetate for the treatment of multiple sclerosis.
Developed by Teva, rasagiline was initially discovered by two Haifa Technion professors, John Finberg and Moussa Youdim, who were instrumental in the early clinical development of the anti-Parkinson drug.
Parkinson’s disease is a degenerative disorder of the central nervous system, whose symptoms include shaking, rigidity, slowness of movement and difficultly with walking as well as dementia in advanced stages. An estimated seven to 10 million people suffer from the disease across the world according to the Parkinson’s Disease Foundation.
According to Teva’s website, rasagiline is a monoaxmine oxidase B (MAO-B) inhibitor that increases available synaptic dopamine in the brain, which might improve the motor symptoms characteristic of Parkinson’s, slowing the progression of the disease.
“Rasagiline has an established safety and efficacy profile…[it] will be an important product for Japan, where the number of available treatment options for Parkinson’s disease remains limited,” said Dr. Hayden.
About the Author: Anav Silverman is a regular contributor to Tazpit News Agency.
If you don't see your comment after publishing it, refresh the page.
Comments are closed.
The New York premier of Sony’s new film, “The Interview” has been scrapped due to a terror threat.
Harvard boycotts SodaStream to avoid offense to Palestinian Arab students.
FM Avigdor Liberman refuses meeting in Jerusalem with Swedish counterpart over PA recognition.
Two-thirds of the Palestinian Authority fears criticizing leader Mahmoud Abbas, according to the latest poll. Does he still represent the PA people?
After 5 years in jail, Cuba has released Jewish-American Alan Gross.
The Cincinnati case helped clarify what cities can and cannot do concerning access to public places.
In the boy’s bag police found a Chanukiah, oil candles and matches.
The European Jewish Congress (EJC) has expressed outrage over the removal of Hamas from the European Union’s list of officially designated terror organizations, after the European Court of Justice in Luxemburg accepted an appeal filed by Hamas against its inclusion in the list. “We have reached a new low in moral relativity if an organization […]
Jeb Bush announced his intention to “actively” explore the presidency in a Christmas and Hanukkah greeting message. “Merry Christmas and Happy Hanukkah!” the former Florida governor Bush said in a Facebook message posted Tuesday. He described conversations he had with his family over Thanksgiving. “As a result of these conversations and thoughtful consideration of the […]
“We are not satisfied with the European Union’s explanation that the removal of Hamas from its list of terrorist organizations is a ‘technical matter,” ‘Prime Minister Benjamin Netanyahu said on Wednesday following the decision of the General Court of the European Union. “The burden of proof is on the European Union and we expect it […]
Two-thirds of Palestinian Authority Arabs in Judea and Samaria are afraid to express criticism of Mahmoud Abbas, according to a survey carried out by the Palestinian Policy and Research Center. The poll was conducted after Abbas ordered the arrest of leaders of the Palestinian Authority’s largest workers’ union, which he also outlawed.
High housing prices are blamed, but has anyone suggested that working for a living might help?
The decision may boomerang on Hamas once the court studies new evidence to prove Israel’s case.
“This is the earliest evidence of the use of olive oil in the country, and perhaps the entire Mediterranean basin.”
I wanted to proclaim that Israel is not occupying any land and has Biblical and strategic rights to Judea and Samaria and a unified Jerusalem.”
President Rivlin commented that Angola has a central role in Africa. “We are impressed by your progress in the area of water and agriculture, and successful use of natural resources,” Rivlin told the Angolan ambassador.
Hungarian-Israeli Scientific Society Established at Bar-Ilan University
As part of a joint Yad Vashem project, Israeli border police stationed in Jerusalem ‘adopt’ Holocaust survivors living in neighborhoods across the capital.
Over 200 hair salons across Israel took part in the annual nationwide drive to collect hair for the Zichron Menachem Cancer Support in Israel in partnership with Pantene Products Israel.
Israeli scientists at Ben Gurion University of the Negev have discovered an earlier way to diagnose brain damage.
Printed from: http://www.jewishpress.com/news/breaking-news/tevas-parkinson-drug-now-marketed-in-japan/2014/05/29/
Scan this QR code to visit this page online: